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Intermittent administration of parathyroid hormone (1-37) im- In healthy subjects and in patients with secondary hy-
proves growth and bone mineral density in uremic rats. perparathyroidism, PTH is secreted in a pulsatile fashion
Background. Parathyroid hormone (PTH) is secreted in a [1–3]. In many hormonal systems, the pulsatile patternpulsatile fashion. Continuous infusion of PTH(1-84) resulted
of secretion has a major impact on the action of thein a net decrease in trabecular bone volume. Differential effects
have been reported following an intermittent application of hormone [4–6]. Likewise, the influence of exogenous
PTH. We investigated the effects of a continuous infusion and PTH on bone morphology seems to be fundamentally
of an intermittent (2 times daily subcutaneously) administra- dependent on the mode of administration. While contin-tion of PTH(1-37) on growth and bone mineral density (BMD)
uous administration induced an increase in bone turn-in healthy and uremic rats.
Methods. Two-stage subtotal nephrectomy was performed over with predominating bone resorption and a net de-
on 130 g female Sprague-Dawley rats. PTH(1-37) or solvent crease in the trabecular bone volume [7, 8], intermittent
was administered through minipumps in sham-operated and administration of PTH resulted in a net stimulation of
uremic rats (60 mg/kg 3 day for 2 weeks). The effect of intermit-
bone formation. In normal as well as osteopenic rats,tent administration was tested with a subcutaneous injection
intermittent administration of PTH improved bone mass,of solvent: 30 mg/kg PTH(1-37) two times per day, 100 pmol
calcitriol (C)/kg two times per day, or both. The length (snout- bone mineralization, and biomechanical properties [9–13].
tailtip) and BMD were measured at the start of uremia and In clinical trials in women with postmenopausal osteopo-
at sacrifice. BMD was measured by peripheral quantitative
rosis, PTH as a daily injection resulted in an increase incomputer tomography at the proximal tibia, 6 and 12 mm distal
bone mass [14].of the kneejoint space. Femur bone morphology was assessed
by x-rays, and calcium content was measured by atomic absorp- Although severe secondary hyperparathyroidism
tion spectrophotometry. leads to destruction of metaphyseal growth zones and
Results. Length gain was not altered by the continuous infu-
by this impairs skeletal growth [15], PTH may stimulatesion of PTH. In contrast, it was significantly increased by inter-
skeletal growth in different settings. PTH stimulatedmittent PTH (control solvent 5.35 6 0.37 cm vs. control PTH
6.19 6 0.47 cm; uremia solvent 4.78 6 0.20 cm vs. uremia PTH DNA synthesis, cell proliferation, and colony formation
6.17 6 0.36 cm; P , 0.05). Intermittent PTH but not C increased in chondrocyte monolayer or suspension cultures in a
BMD in uremic rats (D total BMD 134 1 13.3 vs. 76.3 6
biphasic manner [16]. In vivo treatment of young healthy11.5 mg/mL; P , 0.05). X-rays revealed increased bone mass
rats with 50 mg/kg/day PTH(1-34) induced a modest in-following treatment with PTH but not with C. Uremia de-
creased bone calcium content (64 6 0.3 vs. 73.3 6 2.5 mg/mL), crease in femora length gain after 15 days [17]. A pro-
which was normalized by PTH (80 6 3.6 mg/mL, P , 0.05) longed treatment with PTH(1-34) for six months in
but not by C (69 6 1.9 mg/mL).
healthy and ovariectomized rats was also reported toConclusion. Pulsatile administration of PTH does not ad-
induce an increase in bone quality [18].versely affect, but improves longitudinal growth independent of
concomitant treatment with C. At the same time PTH increases We reasoned that a continuous administration of PTH
BMD and the calcium content of bone. by a minipump system may not replicate the pulsatile
mode of endogenous secretion. Therefore, we tested to
what extent a continuous or an intermittent subcutane-Key words: parathyroid hormone, bone mineral density, growth, ure-
ous treatment with 30 mg PTH(1-37)/kg two times permia, trabecular bone volume
day with or without the coadministration of 1,25(OH)2D3Received for publication May 24, 1999
stimulates longitudinal growth and increases bone min-and in revised form October 22, 1999
Accepted for publication November 2, 1999 eral density (BMD) in young uremic rats and control
animals.Ó 2000 by the International Society of Nephrology
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METHODS Experiment 4
Experimental animals Effect of parathyroid hormone and/or 1,25(OH)2D3 on
bone mineral density in uremic rats. Subtotal nephrecto-Female Sprague-Dawley rats (Fa. Ivanovas, Kissleg/
mized animals were randomized into four treatmentAllga¨u, Germany) were used for the experiments. They
groups on the analogy of experiment 3 (N 5 11 perwere kept individually in a light-controlled (12-h on/off
group): solvent, 1,25(OH)2D3, PTH, 1,25(OH)2D3 1cycles), temperature-controlled (248C), and humidity-
PTH. A control group with 11 sham-operated solvent-controlled (70%) room and were allowed to adapt to
treated animals was added. The duration of the experi-the new environment for seven days.
ment was three weeks. BMD was measured by peripheralAll animals had free access to food (Altromin C 1000
quantitative computer tomography (pQCT; discusseddiet; Altromin Co., Lage, Lippe, Germany) and deionized
later in this article) at start of uremia and prior to sac-water, except for the control animals in experiment 2. The
rifice.diet contained 13800 kJ/kg, 17% protein (wt/wt), 0.95%
calcium, 0.75% phosphorus, and 500 IU/kg vitamin D3. MeasurementsThe day prior to the first operation, the animals were
All measurements of body weight were performed inassigned to the different experimental groups according
nonfasted animals in the morning. The length gain wasto their body weight. A two-stage subtotal nephrectomy
measured under general anesthesia (30 mg/kg Ketanest;(NX) was performed as described earlier [19]. Seven
Park Davis Company, Berlin, Germany; and 2 mg/kgdays after subtotal NX, the contralateral kidney was
Valium; Hoffmann la Roche, Grenzach-Wyhlen, Ger-removed. The mean weight of the animals was 133.5 6
many) during the second-stage operation and prior to6.4, 130 6 8.7, 134 6 9.2, and 125 6 7.9 g in experiments
sacrifice. The last hormone injection was performed 121, 2, 3, and 4 when uremia was established. Control
hours before sacrifice. Blood from the abdominal aortaanimals were sham operated (renal decapsulation).
was collected for serum analyses of calcium, phospho-
Experiment 1 rous, sodium, potassium, alkaline phosphatase, serum
creatinine, and serum urea. During the last 24 hours ofEffect of continuous parathyroid hormone in uremic
experiment 3, the animals were kept in metabolic cagesand healthy animals. In healthy and uremic animals, os-
to obtain 24-hour urine samples. Serum and urine bio-motic minipumps (Alzet 2002; ALZA Corporation, Palo
chemistry were analyzed using a multichannel autoana-Alto, CA, USA) were implanted subcutaneously at the
lyzer (Synchron CX7; Beckmann, Hamburg, Germany).day of the second operation for subtotal NX. The mini-
Creatinine was determined by a kinetic method accordingpumps either infused 60 mg/kg 3 day of human recombi-
to Jaffe´ without deproteinization; the within-assay coef-nant PTH(1-37) (Boehringer Co., Mannheim, Germany)
ficient of variation was ,3%. PTH was measured usingat a pumping rate of 0.5 mL/h or solvent (N 5 7 per
an aminoterminal sensitive immunoradiometric assaygroup). The duration of the experiment was 14 days.
with one receptor specific for the rat aminoterminal re-
Experiment 2 gion 1 through 13 and a second antibody specific for the
midregional sequence 14 through 34 (Nichols Institute,Effect of intermittent parathyroid hormone in uremic
San Juan Capistrano, CA, USA). This assay did not dis-and healthy animals. Uremic and sham-operated rats were
criminate between endogenous and exogenous PTH(1-37).randomized for treatment with twice daily vehicle solution
The intra-assay coefficient of variation was 5.3%.subcutaneously or with PTH [60 mg PTH(1-37)/kg 3 day
given in 2 doses subcutaneously; N 5 7 per group]. The
Evaluation of bone for mineral density andduration of experiment (uremia and treatment) was 14
calcium contentdays. The sham-operated control animals were pair fed.
Bone architecture was evaluated by x-rays of the right
Experiment 3 femur after sacrifice, and femur volume was measured
by water immersion. The specimen were dried at 808CUremic animals concomitantly treated with parathyroid
for 24 hours, weighed, and then ashed in a muffle (Ther-hormone and 1,25(OH)2D3. All animals underwent sub-
micon T, Heraeus) at 6008C for 24 hours. Calcium con-total NX and were randomized into four different treat-
tent was determined using an atomic absorption spectro-ment groups (N 5 11 per group): solvent, 200 pmol
photometer (2100 AAS; Perkin-Elmer, Norwalk, CT,1,25(OH)2D3 kg body wt/day subcutaneously divided in
USA), and bone calcium content was defined as a per-two doses (Roche Company, Grenzach-Wyhlen, Ger-
centage of ratio of bone calcium to volume.many); 60 mg PTH(1-37)/kg body wt/day subcutaneously
Bone mineral density was evaluated by peripheraldivided in two doses; and the combination of both,
pQCT. Measurements were carried out in the proximalPTH(1-37) and 1,25(OH)2D3. The duration of experi-
ment was 14 days. tibia metaphysis (6 mm distal to the kneejoint space)
Schmitt et al: Intermittent PTH in uremia1486
Table 1. Effect of treatment with parathyroid hormone (1-37) [PTH(1-37; 30 mg/kg b.i.d. s.c.)] for 14 days on growth and serum biochemistry
in sham-operated pair fed controls and uremic rats (experiment 2, N 5 7 per group)
Controls solvent Controls PTH Uremia solvent Uremia PTH
Serum creatinine mg/dL 0.3860.02a 0.4560.03a 0.7260.02b 0.67 60.05b
Serum calcium mmol/L 2.4760.07a 2.5160.08a 2.4460.17a 2.2660.15a
Serum phosphate mmol/L 2.4460.09a 2.7460.19a 2.6660.14a 2.4860.17a
D Weight gain g 44.462.5a 52.868.1a 41.263.2a 51.367.9a
Food conversion ratio g/g 0.2360.01a 0.2660.03a 0.2360.01a 0.2660.02a
Length gain cm 5.3560.37a 6.1960.47b 4.7860.20a 6.1760.36b
Data given as mean 6 SEM. The overall effects of the different treatment options were analyzed by ANOVA, followed by Duncan’s test for multiple comparisons
to analyze the differences between each treatment group. Superscript letters indicate significant differences between groups. Values sharing common superscripts
are not significantly different, while values without common superscripts are significantly different (P , 0.05).
and diaphysis (12 mm distal to the kneejoint) 24 hours
prior to the second-stage operation and at sacrifice using
an XCT-960A from Stratec (Pforzheim, Germany). A
voxel size of 0.092 3 0.092 3 1 mm and threshold for
cancellous bone of 0.700 were chosen throughout the
experiment. The threshold for cortical bone was 0.930
with the exception of 0.750 at the 6 mm site at the endos-
teal layer in order to delineate cancellous from cortical
bone (Contour mode 1, Peel mode 2, Cortical mode 2).
The coefficient of variation with repeated positioning of
the limbs was found to be 2.1% for total density, 3.5%
for trabecular density, and 1.8% for cortical density.
Since it has not been possible to perform pQCT in all
animals at the same day, the experiment was performed
within three days. This means that the subtotal NX,
pQCT measurements, and sacrifice were performed se-
quentially and in a randomized fashion for all treatment
groups.
Statistics
Fig. 1. Length gain in uremic rats treated either with solvent, PTH(1-37)Data are given as mean 6 SEM if not indicated other-
subcutaneously (30 mg/kg b.i.d. subcutaneously), 1,25(OH)2D3 (100wise. The overall effects of the different treatment op- pmol/kg b.i.d. subcutaneously), or both (experiment 3, N 5 11 per group).
Data are given as mean 6 SEM. The overall effects of the differenttions were analyzed by analysis of variance, followed by
treatment options were analyzed by analysis of variance, followed byDuncan’s test for multiple comparisons to analyze the
Duncan’s test for multiple comparisons to analyze the differences be-
differences between each treatment group. P , 0.05 was tween each treatment group. The asterisk denotes significant difference
versus solvent and 1,25(OH)2D3-treated animals (P , 0.05).accepted as statistically significant.
RESULTS
vent-treated uremic rats, mean PTH plasma levels wereEffect of continuous parathyroid hormone (1-37) on
240 6 41 pg/mL compared with 526 6 130 pg/mL ingrowth in healthy and uremic animals (experiment 1)
animals with continuous PTH(1-37) infusion (P , 0.05).In healthy and uremic ad libitum fed animals, 60 mg/
kg 3 day PTH(1-37) or solvent was constantly infused via
Effect of intermittent parathyroid hormone (1-37)minipumps. After two weeks of PTH(1-37) treatment, no
on growth in uremic animals and sham-operatedsignificant differences were noted in mean weight gain
pair fed controls (experiment 2)(data not given) and length gain [control animals: PTH
To evaluate whether intermittent PTH(1-37) adminis-4.2 cm (2.7 to 4.5), solvent 3.7 cm (3.2 to 4.4); uremic
tration has a positive effect on growth, PTH(1-37) wasanimals: PTH 3.9 cm (3.0 to 5.1), solvent 3.5 cm (3.3 to
given subcutaneously (2 3 30 mg/kg 3 day) to uremic4.3), median/range, P 5 NS]. PTH plasma levels at the
and sham-operated, pair-fed control animals. The lengthend of the experiment were 143 6 26 pg/mL in control
gain of those animals was compared with solvent-treatedanimals with solvent infusion compared with 385 6 119
pg/mL in animals with the PTH(1-37) infusion. In sol- controls (Table 1).
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Table 2. Serum and urine biochemistry, body weight gain, and food conversion ratio of uremic rats treated either with solvent, PTH(1-37)
(30 mg/kg b.i.d. s.c.), 1,25 vitamin D3 (100 pmol/kg b.i.d. s.c.), or both (experiment 3, N 5 11 per group)
Solvent Vitamin D3 PTH PTH 1 vitamin D3
Weight gain g 37.461.9a 4061.8ab 45.262.9b 44.566.1b
Food intake g 21366a 20166a 21067a 21465a
Food conversion ratio g/g 0.1860.01a 0.1960.01ab 0.2160.01b 0.2160.01b
Serum creatinine mg/dL 0.5560.03a 0.5160.02a 0.4960.03a 0.5360.01a
Serum urea mg/dL 70.863.4a 6362.9ab 57.463.7b 57.562.1b
Serum calcium mmol/L 2.5960.04a 2.5260.05a 2.4460.05a 2.4760.03a
Serum phosphate mmol/L 2.3960.06a 2.460.03a 2.3960.04a 2.6460.07b
Serum AP U/L 263624a 24369a 275620a 292637a
Urine creatinine mg/kg/day 0.9560.05a 1.0260.05a 1.0560.07a 1.0560.09a
Urine urea mg/kg/day 63.764.4a 63.563.4a 51.569.9a 66.164.6a
Urine calcium lmol/kg/day 1.3460.38a 3.6561.45a 3.1060.85a 3.0060.47a
Urine phosphate lmol/kg/day 11866a 118615a 160623a 13868a
Data are given as mean 6 SEM. The overall effects of the different treatment options were analyzed by ANOVA, followed by Duncan’s test for multiple comparisons
to analyze the differences between each treatment group. Superscript letters indicate significant differences between groups. Values sharing common superscripts
are not significantly different, while values without common superscripts are significantly different (P , 0.05).
Parathyroid hormone (1-37) did not have any system- Peripheral quantitative computer tomography mea-
surements were carried out in the proximal tibia meta-atic effect on serum calcium and serum phosphate. It
did not influence body weight gain and food conversion physis (6 and 12 mm distal to the kneejoint space) at
ratio. However, there was a significant increase in length the start and end of the experiment. Whereas there was
gain in uremic animals, as well as in sham-operated pair no significant difference for BMD at the start, animals
fed controls. PTH plasma levels six hours after a subcuta- treated with PTH(1-37) had a significantly higher BMD
neous injection were 407 6 208 pg/mL. At sacrifice, at the end of the experiment. Figure 3 and Table 3 give the
which was about 12 hours after the last injection, iPTH increase in BMD within the three weeks of the experiment.
levels were 290 6 87 pg/mL. The increase in total BMD was the consequence of
a combined increase in cortical density and trabecular
Effect of concomitant treatment with 1,25(OH)2D3 density (Fig. 3 and Table 3). The increase was noted at
and parathyroid hormone (1-37) on growth in both measurement points, but was more expressed in
uremic animals (experiment 3) the metaphysis adjacent to the growth plate. Further-
As in experiment 2, intermittent subcutaneous more, the intermittent treatment with PTH(1-37) induced
PTH(1-37) significantly increased length gain in uremic a significant increase in the periosteal circumference and
animals (Fig. 1), whereas 1,25(OH)2D3 did not. When a significant decrease in the endosteal circumference,
PTH(1-37) was given together with 1,25(OH)2D3, the both leading to a substantial increase in the cortical area.
effect on length gain was slightly but not significantly In contrast, 1,25(OH) 2D3 given alone or in combination
better compared with PTH(1-37) given alone. with PTH did not have a positive effect on BMD and
In this experiment, PTH(1-37) had a slightly positive the cortical area.
effect on the ratio of weight gain per food intake and In accordance with the changes in BMD, the dry
cumulative weight gain. There was no significant effect weight, as well as the calcium content of bone, was
of either 1,25(OH)2D3 or PTH(1-37) on serum biochem- significantly increased with PTH(1-37) but not with
istry, as well as on biochemical findings of the 24-hour 1,25(OH)2D3 (Table 3).
urine (Table 2).
DISCUSSIONEffect of 1,25(OH)2D3 and parathyroid hormone (1-37)
on bone mineral density and bone calcium content The present experiments demonstrate that intermit-
(experiment 4) tent but not continuous administration of PTH(1-37) in-
creases growth, bone calcium content, and BMD in uremicThe bone architecture of the right femora was evalu-
animals. Concomitant treatment with 1,25(OH)2D3 didated by postmortem x-rays of the animals. As seen from
not influence the effects of intermittent PTH.Figure 2, 1,25(OH)2D3 did not have any obvious effect
Parathyroid hormone is a major humoral regulator ofon bone structure and bone x-ray density. In contrast,
there was a striking increase of cortical thickness as well calcium homeostasis. In addition, it has an anabolic ac-
tion that has been known for decades, but has beenas on metaphyseal x-ray density in animals treated
with PTH(1-37) either alone or in combination with forgotten for awhile.
Bauer, Aub, and Albright first demonstrated in 19291,25(OH)2D3.
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Fig. 2. X-ray analysis of the femora from ure-
mic animals treated with solvent (upper row)
PTH(1-37) (30 mg/kg b.i.d. subcutaneously,
second row), 1,25(OH)2D3 (100 pmol/kg b.i.d.
subcutaneously, bottom row), or both (third
row, experiment 4). PTH(1-37) markedly
increased bone density and cortical bone
thickness.
that PTH could increase skeletal calcium by injecting activity on the skeleton [7–13, 17]. In our experiments,
intermittent PTH had an anabolic effect on the skeleton,parathyroid extract into rats [20]. This result has been
confirmed 1932 by Selye, who extended the experiments but growth was not negatively affected by continuous
PTH. This might be due to the fact that the experimentto dogs [21]. The anabolic effects of PTH has engendered
interest in its pharmacological use during the last decade lasted for only two weeks and that plasma PTH levels
were only increased twofold to threefold by the amountafter recombinant human PTH has become available.
The biological effect of exogenously administered PTH of PTH infused by minipumps per day. Although com-
plete plasma concentration profiles were not measuredcan be anabolic or catabolic, depending on the mode of
administration. Animal studies have convincingly shown following intermittent subcutaneous injections, the 6-
hour and 12-hour measurements showed a transient in-that intermittent PTH administration increases bone
mass, while continuous exposure had a marked catabolic crease in plasma concentration of PTH.
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patic enzyme induction in rats [23]. Another possible
explanation of the observed effects of intermittent
PTH(1-37) administration would be that the transient
suppression of endogenous intact PTH secretion, rather
than actions of the exogenously administered hormone,
was responsible for the changes observed. We previously
observed rapid down-regulation of endogenous iPTH
secretion after administration of PTH(1-37) in the rat
(unpublished results), and such autoinhibitory effects
have also been reported in clinical studies [24]. Although
we cannot rule out an indirect action of PTH(1-37) via
induction of fluctuations of endogenous PTH, this mech-
anism appears to be less likely since PTH(1-37) contains
the amino-terminal fragment and the midregional frag-
ment, which are responsible for the metabolic actions of
PTH in growth cartilage and bone [16, 25]. Moreover,
since PTH(1-37) apparently down-regulates endogenous
PTH secretion by binding to parathyroidal PTH autore-
ceptors, it is likely that the hormone receptor interaction
does not differ to a major degree between PTH(1-84)
and PTH(1-37). On the other hand, intermittent suppres-
sion of endogenous PTH may be a promising therapeutic
alternative, especially in patients with hyperparathyroid-
ism, which would mimic the pulsatile patterns induced
by exogenous PTH administration. The recent advent
of calcium receptor mimetic drugs [26], which selectively
and reversibly suppress endogenous PTH secretion,
opens a new perspective for studies of the differential
metabolic effects of different patterns of endogenousFig. 3. Increase in total bone density per volume obtained by pQCT-
measurements at 6 (upper panel) and 12 mm (lower panel) distal to plasma PTH concentrations.
the knee joint space (experiment 4). The overall effects of the different In experiments with nonuremic rodents, intermittenttreatment options were analyzed by analysis of variance, followed by
exogenous PTH increased not only trabecular bone massDuncan’s test for multiple comparisons to analyze the differences be-
tween each treatment group. The asterisk denotes significant difference but also cortical bone mass [27, 28]. This might be in
vs. solvent and 1,25(OH)2D3 animals (P , 0.05). The absolute increase contrast to expectations of nephrologists who see anof bone mineral density was significant in all groups. However, the
increase of trabecular bone volume in iliac crest biopsiesincrease was significantly higher in PTH(1-37)-treated animals.
in hyperparathyroid patients [29, 30] on the one hand,
but periostal resorptions of the cortical layer in radiologi-
cal investigations on the other hand [15, 31]. Our study
The mechanism by which the profound anabolic effect confirms the experience from experimental studies and
of intermittent in contrast to continuous PTH adminis- extends these to the uremic skeleton. It has been shown
tration is achieved remains to be elucidated. PTH is that the effects of PTH are dose and time dependent,
secreted in a tonic and pulsatile fashion [2]. The oscilla- leading to a major effect during the first six treatment
tory pattern of PTH secretion is profoundly disturbed weeks, primarily at the vertebrae and the upper tibia
in uremia [3]. Moreover, a bimodal diurnal rhythm of [32]. Peripheral QCT measurements in our experiments
PTH secretion exists with maximal plasma concentra- indicated an increase both in cortical and trabecular bone
tions in the late afternoon and in the earlier morning [22]. density at the proximal tibia. It is notable that the cortical
In principle, the pattern-dependent metabolic action of bone became thicker since not only the periosteal cir-
PTH may be determined by an absolute peak concentra- cumference increased, but the endosteal circumference
tion, the nadir concentration, the amplitude, the length decreased (Table 3). It cannot be decided whether this
of the time periods for which certain threshold peak or apparent shrinking of the endosteal circumference was
nadir concentration ranges are transgressed, or by the due to corticalization of the trabecular bone or was in
dynamics, that is, the rate of change in plasma PTH part a measuring artifact due to the insufficient resolu-
concentrations. Of note, the nadir levels have been tions depending on the voxel size of the equipment. In
shown to determine the pattern-specific effects of pulsa- any case, the increased total BMD was paralleled by an
increase in the calcium content of the bone, as verifiedtile versus continuous growth hormone on specific he-
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Table 3. Measurement of bone calcium content and of changes (D) in BMD within 3 weeks in solvent treated sham-operated rats and
uremic rats either treated with solvent, PTH (1-37) s.c. (30 mg/kg b.i.d. s.c.), 1,25 vitamin D3 (100 pmol/kg b.i.d. s.c.) or both for
3 weeks (experiment 4, N 5 11 per group)
Uremia Uremia PTH 1
Control solvent Uremia solvent 1,25(OH)2D3 Uremia PTH 1,25(OH)2D3
Bone dry weight/volume mg/mL 877620a 771624b 921638a 899624a 944621a
Bone calcium content mg/mL 73.362.5ab 6460.3b 6961.9b 8063.6a 8262.6a
PQCT measurements at 6 mm
D Total bone content per slice mg/mm 2.2660.16a 2.0260.13a 1.9660.14a 6.3260.32b 6.9160.45b
D Total bone area mm2 3.2660.15a 2.0960.28b 2.1360.16b 3.9260.28ac 4.1260.39c
D Periosteal circumference mm 1.7460.09a 1.1760.16b 1.2460.09b 2.1460.14ac 2.2160.19c
D Endosteal circumference mm 1.0660.07a 0.1560.17a 0.5060.13a 23.1960.33b 23.1660.53b
D Cortical density mg/ccm 10368a 123610ab 13669ab 157615b 19969c
D Trabecular density mg/mL 11.868.6a 28.9865.6a 23.0565.5a 134615.0b 141617.2b
D Cortical area mm2 1.8460.11a 1.9160.14a 1.5460.14a 6.9360.44b 7.1160.53b
PQCT measurements at 12 mm
D Total bone content per slice mg/mm 2.3560.05a 1.8260.07b 1.9460.09b 2.6860.09c 2.7260.11c
D Total bone area mm2 2.9860.08a 2.1560.13b 2.1860.14b 2.7560.11a 2.7160.17a
D Periosteal circumference mm 2.2160.07a 1.6360.10b 1.7160.09b 2.0860.08a 2.0360.11a
D Endosteal circumference mm 1.3560.08a 0.8860.13b 0.8360.11b 0.7460.12b 0.6960.13b
D Cortical area mm2 1.7760.07a 1.3860.07b 1.4960.07b 2.1460.08c 2.1160.07c
Data are given as mean 6 SEM. The overall effects of the different treatment options were analyzed by ANOVA, followed by Duncan’s test for multiple comparisons
to analyze the differences between each treatment group. Superscript letters indicate significant differences between groups. Values sharing common superscripts
are not significantly different (P , 0.05).
by atomic absorption measurements. Finally, the radio- 1,25(OH)2D3 have been performed. A positive effect of
the concomitant therapy has been reported in osteopo-logical work-up provides evidence that the major
changes in BMD were located within the metaphyseal rotic women [36]; however, these studies were uncon-
trolled. Even animal studies do not provide a definiteareas and within the cortical bone.
Our measurements of BMD do not allow any informa- answer about whether 1,25(OH)2D3 has a direct anabolic
effect on bone or whether its effect is mediated indirectlytion on bone quality. We also do not have a micromor-
phometric analysis of the bone. Nevertheless, it is of through the improvement of calcium balance. There is
evidence from vitamin D-deficient rats and from vitamininterest to note that Capozza et al reported not only
on an increase in BMD, but also showed an increased D receptor knockout animals that 1,25(OH)2D3 is not
essential for the normal function of bone cells [37–39].mechanical strength of the femur in immobilized and
overloaded femurs of PTH(1-38) treated rats [33]. In vitamin D-deficient female rats, PTH increased bone
formation and improved mineral balance obviously with-It is more difficult to interpret clinical studies on PTH
treatment. In a prospective study in 21 osteoporotic out any need of 1,25(OH)2D3 [13].
In the present study in uremic animals, 1,25(OH)2D3women treated for 6 to 24 months with a once daily
injection of PTH(1-34), there was a significant increase did not effect BMD when given either alone or in combi-
nation with PTH(1-37), at least at the given dose. It isin trabecular bone volume, as assessed by paired biop-
sies, and a striking increase in the rate of new bone forma- interesting that Gunness-Hey et al did also not find an
increase in bone mass in young healthy rats with the sametion, as measured by calcium kinetics [34]. In 1997, Lindsay
et al reported on the effect of 400 IU PTH(1-34) in a dose of 1,25(OH)2D3 when given alone or concomitantly
with PTH [40]. Higher doses increased trabecular bonerandomized, controlled study in 34 women with post-
menopausal primary osteoporosis over a three-year pe- dry weight and hydroxyproline content; however, miner-
alization was impaired, and rats became hypercalcemic.riod. They demonstrated an increment of both cortical
and trabecular bone induced by PTH [35]. However, in Erben, Bromm, and Stangassinger provided some evidence
that the pharmacological administration of 1,25(OH)2D3both studies, the patients were on estrogen therapy dur-
ing the treatment with PTH, and it might be possible that was able to elicit a direct anabolic response in ovariecto-
mized rats, whereas calcium supplementation alone wasthe positive effect on cortical bone was dependent on
the concomitant estrogen therapy, whereas an isolated without therapeutic effect [41].
Our study is, to our knowledge, the first to demon-PTH therapy might have the risk of cortical erosions.
Because of the concern and the uncertainty regarding strate a positive effect of intermittent PTH administra-
tion on longitudinal growth of uremic animals. Thesethe net effect of PTH on calcium balance, a “combination
therapy” with PTH and a second “antiresorptive drug” observations confirm indirectly recent in vitro findings
of our group where PTH dose-dependently stimulatedhas been investigated frequently [10, 14, 28]. Among
those studies, several attempts to combine PTH with proliferation of growth plate chondrocytes in a biphasic
Schmitt et al: Intermittent PTH in uremia 1491
cortisol in normal women and patients with Cushing’s disease.manner [16]. There are also clinical observations sup-
J Clin Endocrinol Metab 64:1027–1035, 1987
porting a growth promoting effect of PTH. Children with 6. Spratt DI, Finkelstein JS, Butler JP, Badger TM, Crowley WF
Jr: Effects of increasing the frequency of low doses of gonadotro-hypoparathyroidism and pseudohypoparathyroidism are
pin-releasing hormone (GnRH) on gonadotropin secretion inusually growth retarded, although this may be due in
GnRH-deficient men. J Clin Endocrinol Metab 64:1179–1186, 1987
part to a polyglandular disease that is often noted in 7. Tam CS, Heersche JN, Murray TM, Parsons JA: Parathyroid
hormone stimulates the bone apposition rate independently of itsthose patients [42, 43]. It is also of note that PTH plasma
resorptive action: Differential effects of intermittent and continu-concentrations were positively correlated with growth
ous administration. Endocrinology 110:506–512, 1982
velocity in dialyzed children [44]. There is no contradic- 8. Hock JM, Gera I: Effects of continuous and intermittent adminis-
tration and inhibition of resorption on the anabolic response oftion when we reported earlier that the severest forms
bone to parathyroid hormone. J Bone Miner Res 7:65–72, 1992of renal hyperparathyroidism can lead to metaphyseal
9. Mosekilde L, Sogaard CH, Danielsen CC, Torring O: The ana-
destruction and growth arrest [15]. bolic effects of human parathyroid hormone (hPTH) on rat verte-
bral body mass are also reflected in the quality of bone, assessedIn conclusion, our study confirms and extends to the
by biomechanical testing: A comparison study between hPTH-uremic skeleton of rodents that PTH not only stimulates
(1-34) and hPTH-(1-84). Endocrinology 129:421–428, 1991
bone resorption but also bone apposition. In addition, 10. Mosekilde L, Danielsen CC, Gasser J: The effect on vertebral
bone mass and strength of long term treatment with antiresorptivewe found a positive effect on longitudinal growth. The
agents (estrogen and calcitonin), human parathyroid hormone-mode of administration of exogenous PTH is a major
(1-38), and combination therapy, assessed in aged ovariectomized
determinant of its action and its potent anabolic effect, rats. Endocrinology 134:2126–2134, 1994
11. Mosekilde L, Reeve J: Treatment with PTH peptides, in Osteopo-for example, improvement in growth and BMD. It re-
rosis, edited by Marcus R, Feldman D, Kelsey J, New York,mains to be shown in further studies whether the modula-
Academic Press, 1996, pp 1293–1311
tion of PTH levels into a more pulsatile pattern is able 12. Dobnig H, Turner RT: The effects of programmed administration
of human parathyroid hormone fragment (1-34) on bone histomor-to improve the low bone turnover state in uremic patients
phometry and serum chemistry in rats. Endocrinology 138:4607–as it does in postmenopausal osteoporosis. Since a can-
4612, 1997
cerogenic potential of PTH(1-37) has recently been 13. Toromanoff A, Ammann P, Mosekilde L, Thomsen JS, Riond
JL: Parathyroid hormone increases bone formation and improvesnoted in rodents after long-term administration (per-
mineral balance in vitamin D-deficient female rats. Endocrinologysonal communication, Werner Blum, M.D.), recombi-
138:2449–2457, 1997
nant human PTH will not be available for clinical studies 14. Masiukiewicz US, Insogna KL: The role of parathyroid hormone
in the pathogenesis, prevention and treatment of postmenopausalin the near future. It is, however, tempting to speculate
osteoporosis. Aging (Milano) 10:232–239, 1998that similar effects as presented in this study might be 15. Mehls O, Ritz E, Krempien B, Gilli G, Link K, Willich E,
obtained by modulation of iPTH plasma levels with in- Scharer K: Slipped epiphyses in renal osteodystrophy. Arch Dis
Child 50:545–554, 1975termittent administration of calcimimetic agents [45].
16. Klaus G, von Eichel B, May T, Hugel U, Mayer H, Ritz E,
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